GDM Patients and Serum Amyloid A and Interleukin-1 (IL-1) Receptor Antagonist
NCT ID: NCT04238936
Last Updated: 2020-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
80 participants
OBSERVATIONAL
2020-01-20
2020-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Comparison of pregnant women with and without GDM diagnosis
* Comparison of insulin therapy and diet-regulated GDM patients
* Comparison of pregnant women with and without LGA (large gestational age)
* Comparison of pregnant women with and without polyhydroamnios
* Investigation of its effect on pregnancy prognosis
* In the prediction of GDM diagnosis, it is aimed to study the sensitivity and specificity of both parameters and cut off values.
(In GDM patients, liver and kidney function parameters will also be evaluated with A-SAA and IL-1Ra levels).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trimester Sequential Estimation of Serum Zonulin as a Predictor of Gestational Diabetes Mellitus
NCT06336512
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
NCT03377699
Pregnancy on Oral Glucose Tolerance Test Implementation Status, Knowledge, and Anxiety Level
NCT05686694
Afamin in Gestational Diabetes Mellitus
NCT04054843
Serum Endocan Levels and Gestational Diabetes
NCT05237895
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
study group ; Patients with gestational diabetes
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Serum amyloid A values
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
control group ; healthy pregnant women
Women who are healthy pregnant women, the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Serum amyloid A values
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Serum amyloid A values
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Interleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with 75 gr OGTT + at 24-28 weeks of gestation
* 18-42 years pregnant women
Exclusion Criteria
* Any known fetal chromosomal or structural anomaly
* Preterm membrane rupture
* Preterm delivery
* Preeclampsia or eclampsia
* Placenta previa
18 Years
42 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kanuni Sultan Suleyman Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pınar Kadirogulları
principal investigator, Pınar kadirogullari, M.D, Department of Obstetrics and Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kanuni Sultan Süleyman Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ATADEK-2020/02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.